Michael Ian Waterman

US Patent:

20020031782, Mar 14, 2002

Filed:

Feb 28, 2001

Appl. No.:

09/796138

Inventors:

Michael Waterman - Nashville TN, US
Aouatef Bellamine - Nashville TN, US
Larissa Podust - Hermitage TN, US

International Classification:

C12N009/00
G01N033/53
G06F019/00
G01N033/48
G01N033/50

US Classification:

435/007100, 702/019000, 435/183000

Abstract:

A cytochrome P450 14-demethylase enzyme isolated from designated as MT CYP51. A crystalline form of MT CYP51 is also disclosed. Nucleic acid molecules encoding MT CYP51 are also disclosed. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to MT CYP51, and methods of producing the same, are also disclosed. MT CYP51 is characterized as having 14-demethylase biological activity. Thus, therapeutic and drug screening methods pertaining to this activity are also disclosed.

US Patent:

20020052031, May 2, 2002

Filed:

Jul 20, 2001

Appl. No.:

09/909903

Inventors:

Michael Waterman - Nashville TN, US
Aouatef Bellamine - Nashville TN, US

International Classification:

C12N009/02
C07H021/04
C12N005/06
C07K016/40

US Classification:

435/189000, 536/023200, 530/388260, 435/338000

Abstract:

A cytochrome p450 14-demethylase enzyme isolated from designated as MT CYP51. A crystalline form of MT CYP51 is also disclosed. Nucleic acid molecules encoding MT CYP51 are also disclosed. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to MT CYP51, and methods of producing the same, are also disclosed. MT CYP51 is characterized as having 14-demethylase biological activity. Thus, therapeutic and drug screening methods pertaining to this activity are also disclosed.

US Patent:

20020165208, Nov 7, 2002

Filed:

Aug 29, 2001

Appl. No.:

09/942429

Inventors:

Jorge Capdevila - Nashville TN, US
Michael Waterman - Nashville TN, US
Vijakumar Holla - Nashville TN, US

International Classification:

A61K031/56

US Classification:

514/169000

Abstract:

This invention relates generally to compositions and methods relating to hypertension. The present invention provides a method of enhancing the activity of Cyp 4A14 by administering an agent thatenhances the activity of Cyp 4A14 as well as a method of inhibiting the activity of Cyp 4A14 by administering an agent that inhibits the activity of Cyp 4A14. Further provided, is a method of enhancing the activity of Cyp 4A12 by administering an agent that enhances the activity of Cyp 4A12 as well as a method of inhibiting the activity of Cyp 4A12 by administering an agent that inhibits the activity of Cyp 4A12. A method of enhancing the activity of Cyp 4A12 by administering an agent that inhibits the activity of Cyp 4A14 is also provided. The invention also provides a method of inhibiting the activity of Cyp 4A12 by administering an agent that enhances the activity of Cyp 4A14. Further provided is a method of enhancing the activity of human Cyp 4A11 by administering an agent that enhances the activity of human Cyp 4A11 as well as a method of inhibiting the activity of human Cyp 4A11 by administering an agent that inhibits the activity of human Cyp 4A11.

US Patent:

20030087257, May 8, 2003

Filed:

Apr 10, 2002

Appl. No.:

10/120931

Inventors:

Pavel Pevzner - La Jolla CA, US
Haixu Tang - Los Angeles CA, US
Michael Waterman - Dayton NV, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435/006000, 702/020000

Abstract:

A new Eulerian Superpath approach to fragment assembly in DNA sequencing that resolves the problem of repeats in fragment assembly is disclosed. The invention provides for the reduction of the fragment assembly to a variation of the classical Eulerian path problem. This reduction opens new possibilities for repeat resolution and allows one to generate provably optimal error-free solutions of the large-scale fragment assembly problems.